Treatable traits in the NOVELTY study: assessing complexity by network analysis
R. Faner (Barcelona, Spain), E. Rapsomaniki (Cambridge, United Kingdom), R. Beasley (Wellington, New Zealand), R. Hughes (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), A. Papi (Ferrara, Italy), I. Pavord (Oxford, United Kingdom), A. Agustí (Barcelona, Spain)
Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Faner (Barcelona, Spain), E. Rapsomaniki (Cambridge, United Kingdom), R. Beasley (Wellington, New Zealand), R. Hughes (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), A. Papi (Ferrara, Italy), I. Pavord (Oxford, United Kingdom), A. Agustí (Barcelona, Spain). Treatable traits in the NOVELTY study: assessing complexity by network analysis. 1593
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: